AML-058: First-In-Human Study of a Trail Receptor Agonist Fusion Protein, Eftozanermin Alfa, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Diffuse Large B-Cell Lymphoma
Mojca Jongen‐Lavrencic(Erasmus MC Cancer Institute), Daniel Morillo(Hospital Universitario Fundación Jiménez Díaz), Rogier Mous(University Medical Center Utrecht), Dimple Modi(AbbVie (United States)), Emiliano Calvo(South Texas Accelerated Research Therapeutics), Adam J. Olszewski(Memorial Hospital of Rhode Island), Adam M. Petrich(AbbVie (United States)), Silpa Nuthalapati(AbbVie (United States)), Junichiro Yuda(National Cancer Center Hospital East), Monica Motwani(AbbVie (United States)), Sudhir Penugonda(ClearMotion (United States)), Marcel Nijland(University Medical Center Groningen), Yunming Mu(Revolution Medicines (United States)), Sameem Abedin(Medical College of Wisconsin)
Cited by 2
Related Papers
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
|The Lancet Oncology|2016|1.3k
The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation
|AIDS|2014|385